Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study

Sun Hwa Kim, Sin Gon Kim, Doo Man Kim, Jeong Taek Woo, Hak Chul Jang, Choon Hee Chung, Kyung Soo Ko, Jeong Hyun Park, Yong Soo Park, Sang Jin Kim, Dong Seop Choi

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.

Original languageEnglish
Pages (from-to)e27-e30
JournalDiabetes Research and Clinical Practice
Volume110
Issue number3
DOIs
Publication statusPublished - 2015 Dec 1

Bibliographical note

Funding Information:
This study was supported by the Medicine and Bio Project for ‘Development of New Medicine and Medical Material’ (Project No. 70007613, entitled ‘Clinical development of lobeglitazone, a thiazolidinedione insulin-sensitizing agent for diabetes mellitus’) of the Chungcheong Leading Industry Office of the Korea Ministry of Knowledge Economy, which is a government organization. SGK's contribution was supported by a grant of the Korean Health Technology R&D Project (HI14C1731), Ministry of Health & Welfare, Republic of Korea. The research foundations had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.

Publisher Copyright:
© 2015 Elsevier Ireland Ltd.

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study'. Together they form a unique fingerprint.

Cite this